What is the first-line treatment for major depressive disorder?

First-Line Treatment for Major Depressive Disorder

For moderate to severe major depressive disorder, initiate treatment with either cognitive behavioral therapy (CBT) monotherapy OR a second-generation antidepressant (SGA) monotherapy, selected based on adverse effect profiles, cost, and patient preferences. 1

Treatment Selection Algorithm

For Moderate to Severe MDD

Choose between three evidence-based options:

• CBT monotherapy - Moderate-quality evidence shows equivalent efficacy to SGAs for response and remission rates after 8-52 weeks 2
• SGA monotherapy - Strong recommendation with moderate-quality evidence; all SGAs demonstrate similar efficacy 3
• Combination therapy (CBT + SGA) - Conditional recommendation with low-certainty evidence; may provide modest additional benefit (SMD 0.30 over psychotherapy alone, 0.33 over medication alone) 4, 1

For Mild MDD

Initiate CBT monotherapy as first-line treatment (conditional recommendation, low-certainty evidence). 1

Selecting Among Second-Generation Antidepressants

All SGAs have equivalent efficacy—no single agent demonstrates superior effectiveness for symptom improvement. 3 The choice should be driven by:

• Adverse effect profiles: Bupropion causes fewer sexual side effects than fluoxetine or sertraline; paroxetine has higher rates of sexual dysfunction than fluoxetine, fluvoxamine, nefazodone, or sertraline 3
• Cost considerations 3
• Common adverse events to discuss: constipation, diarrhea, dizziness, headache, insomnia, nausea, sexual dysfunction, and somnolence 3
• Suicide risk: SSRIs carry increased risk for nonfatal suicide attempts compared to placebo 3

Critical Monitoring Requirements

Begin monitoring within 1-2 weeks of treatment initiation (strong recommendation, moderate-quality evidence). 3 Assess for:

• Suicidal thoughts and behaviors (highest risk during first 1-2 months) 3
• Agitation, irritability, or unusual behavioral changes 3
• Therapeutic response and adverse effects 3

Response Assessment Timeline

Evaluate treatment response at 6-8 weeks. 3 If inadequate response occurs:

• 38% of patients do not achieve treatment response during 6-12 weeks of SGA treatment 3
• 54% do not achieve remission 3

Duration of Continuation Therapy

Continue treatment for 4-9 months after achieving satisfactory response in first-episode MDD (strong recommendation, moderate-quality evidence). 3

For patients with ≥2 prior episodes, extend treatment duration to years or lifelong to prevent recurrence. 3

Evidence Regarding Combination Therapy

Combination therapy (psychotherapy + antidepressant) demonstrates superiority over monotherapy, particularly for severe or chronic depression. 4 Network meta-analysis shows greater symptom improvement with combined treatment versus psychotherapy alone (SMD 0.30) or medication alone (SMD 0.33). 4

Safety Considerations for High-Risk Populations

Psychotherapy-only demonstrates lower rates of serious adverse events (suicide attempts, psychiatric ED visits, psychiatric hospitalization) compared to combined treatment (1.9% vs 3.7%) and ADM-only (3.0% vs 5.6%). 5 For children and adolescents at high risk, prioritize psychotherapy; for high-risk adults, consider combined treatment. 5

Common Pitfalls to Avoid

• Do not assume one SGA is more effective than another—efficacy differences do not exist across age, sex, or racial/ethnic subgroups 3
• Do not delay monitoring—suicide risk peaks in the first 1-2 months 3
• Do not discontinue prematurely—continue for minimum 4-9 months even after symptom resolution 3
• Do not ignore adverse effects—nausea and vomiting are the most common reasons for discontinuation 3